Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats

M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade

. 2021 ; 89 (3) : 510-517. [pub] 20200501

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK Free Medical Journals from 1967 to 1 year ago
ProQuest Central from 2016-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2016-01-01 to 1 year ago
Public Health Database (ProQuest) from 2021-01-01 to 2021-12-31

BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012534
003      
CZ-PrNML
005      
20220506130146.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41390-020-0926-2 $2 doi
035    __
$a (PubMed)32357361
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Blankestijn, Maaike $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
245    10
$a Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats / $c M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade
520    9_
$a BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
650    _2
$a zvířata $7 D000818
650    _2
$a žluč $x chemie $7 D001646
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a bilirubin $x chemie $7 D001663
650    _2
$a kyselina chenodeoxycholová $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D002635
650    _2
$a cholesterol $x metabolismus $7 D002784
650    _2
$a Criglerův-Najjarův syndrom $x metabolismus $x terapie $7 D003414
650    _2
$a dietní tuky $x farmakokinetika $7 D004041
650    _2
$a ezetimib $x farmakologie $x terapeutické užití $7 D000069438
650    _2
$a feces $x chemie $7 D005243
650    _2
$a haptoglobiny $x analýza $7 D006242
650    _2
$a fluorované uhlovodíky $x farmakologie $x terapeutické užití $7 D006845
650    _2
$a hyperbilirubinemie $x terapie $7 D006932
650    _2
$a střeva $x účinky léků $x metabolismus $7 D007422
650    _2
$a lipidy $x krev $7 D008055
650    _2
$a jaterní receptor X $x metabolismus $7 D000071518
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a PPAR delta $x metabolismus $7 D047494
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Gunn $7 D011911
650    _2
$a receptory cytoplazmatické a nukleární $x metabolismus $7 D018160
650    _2
$a sulfonamidy $x farmakologie $x terapeutické užití $7 D013449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van de Peppel, Ivo P $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
700    1_
$a Dvorak, Ales $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
700    1_
$a Capkova, Nikola $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
700    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
700    1_
$a Jonker, Johan W $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
700    1_
$a Verkade, Henkjan J $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. h.j.verkade@umcg.nl
773    0_
$w MED00003741 $t Pediatric research $x 1530-0447 $g Roč. 89, č. 3 (2021), s. 510-517
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32357361 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130138 $b ABA008
999    __
$a ok $b bmc $g 1789933 $s 1163735
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 89 $c 3 $d 510-517 $e 20200501 $i 1530-0447 $m Pediatric research $n Pediatr Res $x MED00003741
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...